ONCOPEPTIDES AB Oncopeptides AB announced the approval of price and reimbursement allowing Oncopeptides to start commercializing its drug Pepaxti in Spain as early as in 2024. The company hereby confirms the previously communicated timeline where the first regions in Spain are expected to have access to Pepaxti and sales to commence during the second half of 2024. Following this official approval, the last hurdle to gain national reimbursement in Spain has been cleared and as a next step Pepaxti will be made available within the Spanish healthcare system (?Nomenclator?) and a full launch is expected to commence after summer.
As previously communicated, Oncopeptides deems the agreed price to be in line with its financial projections and to reflect the scientific innovation of Pepaxti.
